Target intelligence / Profile preview

Transcription factor Sp3 (Sp3)

Target
Sp3
Molecular classification
Transcription factor, Krüppel-like factor family (Sp/KLF), Zinc finger protein
01

Overview

Transcription factor Sp3 is a ubiquitously expressed zinc finger transcription factor, highly similar to Sp1, that binds GC- and GT-boxes in gene promoters and regulates gene expression by acting as both an activator and repressor[1][2][3]. It belongs to the Sp/Krüppel-like factor family and is encoded by the SP3 gene in humans[3]. Sp3 plays roles in embryonic development, cell growth, immune responses, and cancer progression; knockout studies show that it is essential for postnatal survival and proper differentiation of tissues such as teeth in mice[1]. Overexpression of Sp3 has been implicated in a variety of cancers, where it promotes proliferation, survival, and invasiveness[4][6][7]. Sp3 has several isoforms generated from alternative translational initiation sites, with distinct regulatory activities[2][3]. While many anticancer drugs can downregulate Sp3 in preclinical models, there are currently no approved drugs that specifically target Sp3 in the clinic[4][6][7].

Other names
Specificity protein 3SP3transcription factor Sp3
02

Mechanism of action

Inhibition or downregulation of Sp3 leads to reduced cancer cell growth, survival, migration, and invasion\nRNA interference or small molecules that induce degradation/downregulation of Sp3 contribute to anti-tumor effects[4][6][7]

03

Biological functions

Regulation of gene transcription (activation and repression)Cell growth and survivalEmbryonic developmentCell proliferation and apoptosisImmune response
04

Disease associations

Cancer (multiple types, including breast, kidney, pancreatic, lung, colon, gastric, head and neck, prostate)Tumor progression and invasivenessPotential roles in immune-related diseases
05

Safety considerations

Notable challenges include functional redundancy with other Sp proteins, which may complicate targeted therapy[6][7]Essential roles in normal development and cell function may raise toxicity concerns if broadly inhibited[1][6]
06

Interacting drugs

Drugs known to downregulate or degrade Sp3 (not clinically approved specifically for Sp3; examples include some anticancer agents that suppress Sp-family transcription factors in preclinical models)

1 more in the full profile.

07

Biomarkers

Overexpression of Sp3 (and related proteins Sp1/Sp4) can serve as a negative prognostic factor or marker in certain cancers[4][7]

Beyond the preview

Go deeper on Transcription factor Sp3 (Sp3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcription factor Sp3 (Sp3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call